Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
TRT (Testosterone Replacement Therapy)Small moleculeNo amino acid sequence. Icon reflects category theme only.Also known as: Test C, Test Cyp, Depo-Testosterone
The TRAVERSE trial followed 5,246 men for a median of 33 months and settled one of medicine's longest running arguments: testosterone replacement does not increase heart attacks or strokes (HR 0.96, 95% CI 0.78 to 1.17). Testosterone cypionate is an FDA approved injectable that restores serum testosterone in men with diagnosed hypogonadism, defined as total T below 300 ng/dL on two separate morning draws. The FDA removed its cardiovascular black box warning in March 2025. Roughly 208,000 members of r/Testosterone track protocols, labs, and dose adjustments in real time, making TRT one of the most community documented therapies in medicine.
Testosterone Replacement Therapy (TRT) is the medical administration of exogenous testosterone cypionate or enanthate to men whose bodies don't produce enough on their own. The TRAVERSE trial (n=5,246)[1] confirmed cardiovascular safety, and the FDA removed its black box warning in March 2025. The diagnostic bar is straightforward: total testosterone below 300 ng/dL on two separate morning blood draws, confirmed by symptoms like fatigue, reduced libido, erectile dysfunction, muscle loss, and depressed mood. Injectable testosterone cypionate comes as a 200 mg/mL oil based solution in 10 mL multi dose vials. Unlike peptides, there's no reconstitution step. You draw directly from the vial with an 18 to 20 gauge needle, switch to a 23 to 25 gauge injection needle, and inject intramuscularly or subcutaneously. The community side of TRT is enormous. Over 208,000 members on r/Testosterone share bloodwork, protocols, and real world outcomes. Community consensus and clinical evidence have converged on twice weekly split dosing (every 3.5 days), subcutaneous injection preference, and avoiding routine aromatase inhibitor use. Corona and colleagues confirmed efficacy for libido, body composition, bone density, and mood across a large meta analysis [2]. Secondary endpoints from TRAVERSE (pulmonary embolism, atrial fibrillation) were raised versus placebo, so risk benefit still requires clinical judgment.
Testosterone cypionate is an esterified prodrug. After intramuscular injection into the gluteal or deltoid muscle, the oil depot releases testosterone cypionate slowly into surrounding tissue. Esterases in the blood cleave the cypionate ester, freeing active testosterone. Free testosterone binds androgen receptors in the cytoplasm of target cells throughout the body. Skeletal muscle, bone, brain, adipose tissue, skin, and reproductive organs all carry these receptors. The testosterone androgen receptor complex moves into the nucleus and is a transcription factor. It binds androgen response elements on DNA and upregulates protein synthesis, particularly myosin heavy chain and local IGF-1 production in muscle. In bone, androgen receptor activation stimulates osteoblast proliferation and inhibits osteoclast activity. Two enzymatic conversions matter clinically. 5 alpha reductase converts testosterone to dihydrotestosterone, a more potent androgen responsible for prostate growth and hair follicle miniaturization. Aromatase converts testosterone to estradiol, which is necessary for bone health and libido but problematic in excess. Rising testosterone and estradiol exert negative feedback on GnRH pulsatility in the hypothalamus. That suppresses LH and FSH from the pituitary. This feedback loop is why exogenous testosterone causes testicular atrophy and impaired spermatogenesis within weeks of starting therapy.
FDA-approved exogenous testosterone restores physiological serum levels in diagnosed hypogonadal men. TRAVERSE trial (n=5,246, NEJM 2023) established non-inferiority for MACE (HR 0.96, 95% CI 0.78–1.17). Strong efficacy evidence for libido, body composition, bone density, mood, and anemia correction. FDA removed cardiovascular black box warning March 2025. Secondary endpoints (PE, AF) remain elevated vs. placebo: risk-benefit still requires clinical judgment.
Lincoff AM et al. Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE). NEJM 2023; PMID 37326322
TRAVERSE enrolled men with pre-existing or high-risk CV disease: generalizability to low-risk younger men uncertain. Secondary endpoints (pulmonary embolism, atrial fibrillation) were elevated vs. placebo. Optimal dosing target range not definitively established in RCTs. Long-term prostate safety data beyond 5 years remains limited.
Described as "life-changing" for symptomatic low T. Strong consensus on split-dose twice-weekly injections, SubQ preference, and avoiding routine AI use. Main frustrations are hematocrit management, estrogen dialing, and injection logistics.
Science and community are strongly aligned on TRT efficacy and core protocols. Community split-dosing practice (E3.5D) and SubQ preference are now supported by clinical evidence. Main community divergence: some members self-administer at upper clinical or supraphysiologic doses without formal hypogonadism diagnosis. Community has largely adopted the clinical consensus against routine AI use.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 80mg | Weekly |
| Moderate | 75mg | 2x/week |
| Aggressive | 100mg | 2x/week |
TRT isn't a peptide. It's exogenous testosterone. But it shows up on this platform because it's commonly stacked with peptides like gonadorelin or HCG for fertility preservation. Testosterone cypionate comes as a ready to use oil solution at 200 mg/mL. No reconstitution math here; you're drawing volume directly. For an 80 mg dose, that's 0.4 mL (40 units on a 100 unit insulin syringe). For the common split dose of 75 mg twice weekly, draw 0.375 mL (37 to 38 units). At 100 mg per injection, you need 0.5 mL (50 units). The thing most beginners miss: warm the vial in your hands for 60 seconds before drawing. Cold oil is thick and painful going in. Splitting your weekly dose into two injections every 3.5 days produces more stable blood levels and reduces estrogen spikes; the community figured this out before the clinical literature caught up. Get baseline bloodwork before your first injection. Total testosterone, free testosterone, estradiol (sensitive assay), SHBG, CBC with hematocrit, PSA, and a lipid panel. Non negotiable.
TRT is a continuous, lifelong therapy, not cycled. Stopping abruptly causes a crash in testosterone levels that can take months to recover from (if natural production recovers at all). If discontinuation is desired, work with an endocrinologist on a PCT protocol using enclomiphene, gonadorelin, or HCG to restart the HPG axis.
TRT is a continuous, lifelong therapy, not cycled. The HPG axis is suppressed by exogenous testosterone within weeks (LH and FSH fall to near-zero). Stopping abruptly causes a testosterone crash that can take months to recover from; in men with primary hypogonadism, natural production may never return. If discontinuation is desired, a medically supervised post-TRT protocol using enclomiphene, gonadorelin, or HCG is required to attempt HPG axis restart. The onWeeks: 52 / offWeeks: 0 cycling entry in peptides.ts reflects this medical reality.
Or use the universal Peptide Calculator for any peptide.
Expected: Total T restored to 400–700 ng/dL trough; symptom improvement in libido, energy, and mood by weeks 3–6; body composition changes by months 3–6
Monitor: Trough total T, free T, E2 (sensitive assay), hematocrit, PSA, lipids, BP at 6 weeks; then 3 months; then every 6–12 months
Wash hands thoroughly and prepare supplies: testosterone vial, alcohol swabs, 18 to 20 gauge drawing needle, 23 to 25 gauge 1 to 1.5 inch injection needle (or 27 to 29 gauge 0.5 inch insulin syringe for SubQ), sharps container.
Oil based testosterone flows more easily when warm, and cold oil causes more post injection pain.
Draw air into the syringe equal to your dose volume, inject air into the vial, then invert and draw your dose. For 80 mg from a 200 mg/mL vial, draw to the 40 unit mark (0.4 mL). For 75 mg, draw to 37 to 38 units (0.375 mL). For 100 mg, draw to the 50 unit mark (0.5 mL).
Tap out air bubbles and push plunger until a small drop appears at the needle tip.
Preferred sites: ventrogluteal (safest, best absorption), vastus lateralis (outer thigh), or deltoid for IM. For SubQ, inject into abdominal or thigh fat.
For IM: insert the needle at 90 degrees in one smooth motion. Aspirate briefly. Inject slowly over 15 to 20 seconds. For SubQ: pinch skin, insert at 45 to 90 degrees, inject slowly.
Withdraw the needle and apply gentle pressure with a cotton ball. Do not rub. Rotate injection sites each time to prevent scar tissue buildup.
Store the vial at room temperature (20 to 25 degrees Celsius). Do not refrigerate or freeze oil based testosterone.
Same mg dose; some patients require 10–20% higher weekly dose SubQ vs. IM to achieve equivalent trough levels due to slower peak absorption from SubQ depot
27–29g 0.5-inch insulin syringe into abdominal fat, thigh, or deltoid fat. Lower peak/trough variation, less E2 spike, less hematocrit elevation vs. IM. Strong patient preference over IM in switch studies. FDA label specifies IM only for Depo-Testosterone, but Xyosted (SubQ testosterone enanthate auto-injector) is FDA-approved SubQ. PMID 34698352 supports clinical equivalence.
1.62% gel: 20.25–81 mg/day applied daily; achieves lower and more variable serum levels than injectable; ~30% effective dose relative to injectable in practice
Transference risk to women and children via skin contact: significant concern in households with partners or children. No injection required. Daily application is adherence burden. More expensive per dose than injectable generic. Preferred by patients who cannot or will not inject.
75–450 mg implanted SubQ every 3–6 months; dose fixed at insertion: no adjustment possible after placement
Consistent serum levels without weekly injections. Irreversible once implanted: side effects cannot be managed by dose reduction until pellets absorb. Minor surgical insertion procedure required. Pellet extrusion rate ~5–8%.
750 mg IM on day 1, again at 4 weeks, then every 10 weeks; extremely infrequent dosing but extreme peaks/troughs
Risk of serious pulmonary oil microembolism (POME) requires 30-minute post-injection observation at a certified healthcare facility: cannot self-inject. Available only through REMS program.
Maintains testicular volume and intratesticular testosterone for fertility preservation during TRT. Acts as an LH analog: stimulates Leydig cells to prevent complete testicular atrophy.
250 IU SubQ every other day (EOD), concurrent with TRT
Modern HCG alternative for LH/FSH stimulation and HPG axis maintenance. More physiologic pulsatile GnRH stimulation vs. sustained LH analog.
50–100 mcg SubQ 2–3×/week concurrent with TRT
Central melanocortin agonist for sexual function; addresses residual ED or libido issues not fully resolved by TRT alone.
1.75 mg SubQ 45–60 min before sexual activity, PRN
Hypothalamic GnRH stimulator; experimental adjunct for HPG axis support. Occasionally stacked by biohackers. No established clinical TRT protocol.
Research use only; no established TRT co-protocol
Routine AI use crashes estradiol: joint pain, low libido, and fatigue from E2 deficiency are identical to high-E2 symptoms, creating a mismanagement cycle. Only use if E2 confirmed elevated by LC-MS/MS AND symptomatic.
Opioids independently suppress the HPG axis (opioid-induced hypogonadism): TRT dose requirements increase and optimization is confounded. Co-administration without monitoring is high-risk.
Testosterone may potentiate anticoagulant effect and increase INR/bleeding risk. Close INR monitoring and potential dose adjustment required if co-prescribed.
Stacking exogenous AAS with TRT provides no additional therapeutic benefit and compounds hematocrit, cardiovascular, and hepatic risks well beyond clinical range.
Do not combinePricing updated 2026-04-09
Hematocrit elevation is the lab abnormality that demands the most attention. Testosterone stimulates erythropoiesis, pushing red blood cell production higher. When hematocrit exceeds 54%, blood viscosity rises and so does clot risk. Therapeutic phlebotomy or dose reduction becomes necessary at that threshold. This isn't a theoretical concern; it's the most common reason clinicians adjust TRT protocols. Testosterone aromatizes to estradiol via the aromatase enzyme. Raised estradiol causes water retention, gynecomastia, and mood instability. The community learned a painful lesson about managing this: routine aromatase inhibitor use crashed estradiol in thousands of men, producing joint pain, low libido, and fatigue identical to high estrogen symptoms. The current clinical consensus reserves anastrozole only for men with LC-MS/MS confirmed raised estradiol AND symptomatic complaints. Acne and oily skin affect roughly 15 to 25% of users. Shoulders and back are the typical sites. DHT mediated hair loss accelerates in men genetically predisposed to male pattern baldness; finasteride blocks this conversion but also limits some androgenic benefits. TRT suppresses the hypothalamic pituitary gonadal axis. Testes shrink. Sperm production drops to near zero in most men within months. Anyone wanting future fertility needs concurrent HCG or gonadorelin to maintain intratesticular testosterone and spermatogenesis. The TRAVERSE trial flagged higher rates of pulmonary embolism and atrial fibrillation versus placebo as secondary endpoints. These findings warrant monitoring, not dismissal. PSA may increase modestly on therapy. Men with untreated prostate cancer or a PSA above 4 ng/mL without urological clearance should not start TRT. Sleep apnea can worsen in susceptible individuals. Mood irritability and increased aggression show up occasionally at supraphysiologic doses but are uncommon at clinical replacement levels. Contraindications are clear: active or history of hormone sensitive prostate cancer, male breast cancer, polycythemia above 54%, severe untreated sleep apnea, uncontrolled heart failure (NYHA Class III to IV), pregnancy or exposure to pregnant women (Category X), and desire for near term fertility without gonadotropin support.
Verify TRT (Testosterone Replacement Therapy) dosing and safety with a second opinion
Pharmaceutical-grade testosterone cypionate is FDA-approved, widely available at US retail pharmacies, and subject to full pharmaceutical QC. Risk is low for prescription-dispensed product. Compounded testosterone (503A/503B pharmacies) carries moderate quality risk due to less stringent batch-to-batch testing. Unregulated or research-grade sources carry high risk.
| Test | When | Target |
|---|---|---|
| Total testosterone (trough) | Baseline, week 6, month 3, month 6, then every 6–12 months | 400–700 ng/dL (trough, immediately before next injection) |
| Free testosterone | Baseline, week 6, when symptoms do not match total T result | 70–150 pg/mL (equilibrium dialysis method preferred) |
| Estradiol sensitive (LC-MS/MS assay) | Baseline, week 6, month 3, whenever E2-related symptoms suspected | 20–40 pg/mL (sensitive assay; do not use standard immunoassay) |
| SHBG | Baseline, then annually or when free T is rechecked | — |
| Hematocrit / CBC | Baseline, week 6, month 3, then every 3–6 months | <54% (hold therapy and investigate if exceeded) |
| PSA | Baseline, month 3, month 6, then annually | Rise <1.4 ng/mL above baseline within 12 months; absolute <4 ng/mL without urological clearance |
| Lipid panel | Baseline, month 6, then annually | — |
| Blood pressure | Baseline, then at each clinical encounter | — |
| Metabolic panel (LFTs, BMP) | Baseline, annually | — |
Confirm dosing achieves target therapeutic range
High SHBG can make normal total T functionally hypogonadal; free T is the bioactive fraction
Aromatization of testosterone to E2; elevated E2 causes water retention and gynecomastia; crashed E2 (from AI overuse) causes joint pain and low libido
Determines bioavailable fraction; high SHBG requires higher total T target to achieve adequate free T
Testosterone stimulates erythropoiesis; hematocrit >54% increases blood viscosity and VTE risk
TRT does not cause prostate cancer but can accelerate pre-existing hormone-sensitive disease; track velocity
Testosterone may modestly reduce HDL; baseline and ongoing CV risk assessment
FDA now requires product-specific BP monitoring language (post-TRAVERSE postmarket ABPM studies); TRT can elevate BP in susceptible individuals
Baseline organ function; LFTs relevant for AI co-administration; renal function for risk stratification
Testosterone levels begin rising within 24-48 hours of the first injection. Most men don't notice subjective changes yet. Slight improvements in energy and mood may appear toward week 2-3. Serum trough levels aren't stable until about 4-5 half-lives (~5-6 weeks).
Libido and sexual function often improve noticeably. Morning erections return in previously hypogonadal men. Energy and motivation begin to pick up. First follow-up labs should be drawn at 6 weeks (trough level, before next injection).
Body composition changes start: early increases in lean mass and reductions in visceral fat. Mood stabilizes. Hematocrit may begin climbing. Estradiol should be checked. Dose adjustments are commonly made at this stage based on bloodwork.
Full effects on muscle mass, strength, and fat loss become apparent. Bone mineral density improvements are measurable. Red blood cell count and hematocrit reach new equilibrium: monitor closely. Lipid panel changes may appear (HDL may decrease slightly).
Maximum therapeutic benefits are reached by 9-12 months. Body composition, mood, libido, and energy reach steady state. Ongoing monitoring every 6-12 months: CBC, metabolic panel, testosterone, estradiol, PSA, and lipids.
Weeks 1 to 3: Testosterone levels start rising within 24 to 48 hours of the first injection, but steady state trough won't arrive for another 5 to 6 weeks. Most men report minimal subjective change during this window. Some notice a slight uptick in energy around week 2 or 3. Patience matters here; your body is catching up to the new supply. Weeks 3 to 6: This is when most men notice something concrete. Morning erections return. Libido picks up in a way that feels different from placebo. Energy and motivation start building. First trough labs should be drawn at week 6, right before your next injection. Don't adjust dose before you have data. Weeks 6 to 12: Body composition changes become visible. Early lean mass gains and reductions in visceral fat start showing. Hematocrit may begin climbing. Estradiol should be checked. This is the window where most dose adjustments happen based on that week 6 bloodwork. The AI debate among community members peaks during this stretch. Months 3 to 6: Full therapeutic effects take hold. Lean mass increases are measurable by DXA. Visceral fat drops. Mood stabilizes into what long term users call "the new normal." Some men need their first therapeutic phlebotomy around this time. PSA and lipid panels should be rechecked. Months 6 to 12 and beyond: Maximum benefits reached by 9 to 12 months. Body composition, libido, energy, and mood reach steady state. Bone density improvements continue accumulating for 2 or more years. Monitoring shifts to every 6 to 12 months: CBC, metabolic panel, testosterone, estradiol, PSA, and lipids.
Testosterone levels rise within 24–48 hours of first injection. Steady-state trough not reached for ~5–6 half-lives (~5–6 weeks). No measurable body composition change possible yet.
Most report minimal change. Some notice slightly improved energy by week 2–3. Occasional temporary acne flare. Libido change minimal or non-existent at this stage.
Serum T approaching steady state. Libido, morning erections, and mood begin responding. First trough labs should be drawn at week 6.
Return of morning erections frequently reported as first concrete signal of effect. Libido noticeably improved. Energy picking up. Labs may confirm T in range but not yet fully optimized.
Hematocrit reaching new equilibrium. Estradiol levels stabilizing. Early lean mass and fat loss becoming measurable. Dose adjustments commonly made at this stage based on week-6 trough labs.
First dose adjustments. AI debates peak during this window. Body composition changes becoming visible. Some report needing AI; majority feel best without it.
Lean mass increases measurable by DXA. Visceral fat reduction apparent. Bone mineral density improvements begin. Lipid panel may show modest HDL reduction. RBC count at new equilibrium.
"Full effect" commonly described at 3–4 months. Strength gains, fat loss, mood stability all reported. Some require first therapeutic phlebotomy. PSA and lipid check advised.
Body composition, libido, energy, and mood at maximum therapeutic benefit. Bone density improvements continue for 2+ years. Ongoing monitoring every 6–12 months.
"The new normal." Most well-dialed in on dose, schedule, and monitoring. Long-term users describe it as permanent lifestyle management rather than a treatment course.
Source: FDA label: terminal half-life ~8 days (192 hours) for testosterone cypionate IM; Bi et al. 2018 population PK study reported median post-hoc half-life of 4.05 days for total testosterone appearance
Loading the interactive decay curve.
Testosterone cypionate (Depo-Testosterone) is FDA approved for the treatment of hypogonadism in men. It is a Schedule III controlled substance under the Controlled Substances Act, requiring a valid prescription from a licensed provider. Generic testosterone cypionate is available at nearly all US retail pharmacies. Compounded testosterone from 503A or 503B pharmacies is also widely available through TRT clinics (Defy Medical, DiscoverTRT, and similar telehealth platforms). Testosterone is prohibited by WADA at all times, both in and out of competition. Athletes subject to anti doping testing should not use TRT without a Therapeutic Use Exemption, which is rarely granted at the professional level. No pending regulatory changes affect injectable testosterone cypionate availability. The March 2025 removal of the cardiovascular black box warning simplified prescribing but added product specific blood pressure monitoring language based on TRAVERSE postmarket data. This content is for informational purposes only and does not constitute medical advice. TRT requires medical supervision, ongoing lab monitoring, and a valid prescription. Consult a qualified healthcare provider before starting testosterone therapy.
Peptide Schedule Research TeamReviewed Apr 20264 Citations
